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Burkholderia cepacia complex (Bcc) bacteria are opportunistic respiratory pathogens which are particularly difficult to eradicate from the
lungs of cystic fibrosis (CF) patients because of their innate resistance to antimicrobials and their capacity to form biofilms. The goal of the present
study was to evaluate the bacteriostatic and bactericidal activities of temocillin against planktonic and sessile Bcc bacteria.
37 strains belonging to 17 Bcc species were tested. 75.7% of the strains were susceptible when grown planktonically (minimal inhibitory
concentration b16 μg/ml). The minimal bactericidal concentrations were higher than 128 μg/ml for most strains. No remarkable differences in
resistance between exponentially growing planktonic cells and 4 h old biofilms were observed: when grown in a biofilm, 59.5% of the strains were
susceptible. After treating 24 h biofilms with a concentration of 10×MIC, only a minor reduction was seen in the number of sessile cells,
indicating a limited bactericidal activity against biofilms.
Our data indicate that temocillin has a good bacteriostatic in vitro activity against planktonic and 4 h old biofilms, but seems of limited use to
eradicate 24 h old biofilms.
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The Burkholderia cepacia complex (Bcc) is a group of 17
different Gram-negative β-Proteobacteria [1]. These versatile
microorganisms are opportunistic pathogens which can cause
severe lung infections in cystic fibrosis (CF) patients and
immunocompromised individuals [2]. In Bcc infected CF
patients, infections with Burkholderia cenocepacia and Burkhol-
deria multivorans are most common and are difficult to treat
because of the high innate resistance of these species to
antimicrobials [2]. This resistance is due to various mechanisms,
including the presence of multidrug efflux pumps, β-lactamases
and altered penicillin binding proteins [3]. Furthermore it has
been described that many Bcc strains readily form biofilms [4].⁎ Corresponding author. Laboratorium voor Farmaceutische Microbiologie,
Universiteit Gent, Harelbekestraat 72, B-9000 Gent, Belgium. Tel.: +32 9
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doi:10.1016/j.jcf.2010.08.015In 2004, temocillin (a semisynthetic 6-α-methoxy β-lactam
antibiotic) was granted orphan drug status for treatment of Bcc
infected patients by the European Medicines Agency [5]. Unlike
several other β-lactam antibiotics, temocillin is not degraded by
most classical and extended-spectrum β-lactamases and AmpC
enzymes [6].
Temocillin has been tested in a limited number of clinical
studies. In a pilot study temocillin in combination with an
aminoglycoside was given iv to five CF patients infected with
both Bcc and Pseudomonas aeruginosa. Improvement occurred
after six of seven courses when temocillin was used as first-line
therapy and after three of five courses when it was used after
failure of other antibiotics [7]. Lekkas et al. [8] also treated Bcc
infected CF patients with iv temocillin in combination with an
aminoglycoside. In 18 of 32 courses of temocillin (56.3%)
(given to 20 patients) improvement occurred, while in 2 courses
(6.3%) there was a partial response and in 12 courses (37.5%)
the treatment failed. In a retrospective study, Kent et al. [9]
showed that iv therapy with temocillin has the same effect ond by Elsevier B.V. All rights reserved.
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antibiotic therapy.
To date, only few in vitro susceptibility data are available for
temocillin [10,11]. A first goal of the present study was to
evaluate the bacteriostatic and bactericidal effects of temocillin
on planktonic Bcc cells. A second goal was to examine its
growth-inhibitory effect on freshly adhered Bcc sessile cells
(=4 h old biofilms) and its bactericidal effect on mature biofilms
(24 h old biofilms).
2. Materials and methods
2.1. Strains and culture conditions
The Bcc strains used are listed in Table 1. Escherichia coli
ATCC 10536 was included as a control strain. All strains were
obtained from the BCCM/LMG Bacteria collection (Ghent,
Belgium) or were kindly provided by Dr. P. Vandamme (GhentTable 1
MICs a, MBCs b and MBICs c for temocillin against 37 Bcc strains.
Strain Origin
B. cepacia LMG 1222T Onion, US
B. cepacia LMG 18821 CF patient, Australia
B. multivorans LMG 13010T CF patient, Belgium
B. multivorans LMG 17588 Soil rhizosphere, US
B. multivorans LMG 18822 CF patient, Canada
B. multivorans LMG 18825 CF patient (epidemic),
B. cenocepacia LMG 16656T CF patient (epidemic),
B. cenocepacia LMG 18828 CF patient (epidemic),
B. cenocepacia LMG 18829 CF patient (epidemic),
B. cenocepacia LMG 18830 CF patient (epidemic),
B. stabilis LMG 14086 Respirator, UK
B. stabilis LMG 14294T CF patient, Belgium
B. vietnamiensis LMG 10929T Oryza sativa, soil, Vie
B. vietnamiensis LMG 18835 CF patient, US
B. dolosa LMG 18941 CF patient, US
B. dolosa LMG 18943T CF patient, US
B. ambifaria LMG 19182T Pea rhizosphere, US
B. ambifaria LMG 19467 CF patient, Australia
B. anthina LMG 20980T Soil, US
B. anthina LMG 20983 CF patient, UK
B. pyrrocinia LMG 14191T Soil, Japan
B. pyrrocinia LMG 21824 CF patient, UK
B. ubonensis LMG 20358T Soil rhizosphere, Thail
B. ubonensis LMG 24263 Nosocomial infection,
B. latens LMG 24064T CF patient, Italy
B. diffusa LMG 24065T CF patient, US
B. diffusa LMG 24266 CF patient, Canada
B. arboris LMG 24066T Soil, US
B. arboris R-132 CF patient, US
B. seminalis LMG 24067T CF patient, US
B. seminalis LMG 24272 Nosocomial infection,
B. metallica LMG 24068T CF patient, US
B. metallica R-2712 CF patient, Canada
B. lata LMG 6992 Soil, Trinidad and Tob
B. lata R-9940 CF patient, Canada
B. contaminans LMG 16227 CF patient, Sweden
B. contaminans R-12710T Sheep's milk, Spain
a Minimal inhibitory concentration; breakpoint concentration=16 μg/ml [14].
b Minimal bactericidal concentration.
c Minimal biofilm inhibitory concentration.University, Belgium). Cells were stored at −80 °C using
Microbank vials (Prolab Diagnostics, Richmond Hill, ON,
Canada) and subcultured on Mueller-Hinton agar (Oxoid,
Hampshire, UK). Overnight cultures were diluted in Mueller-
Hinton broth (Oxoid, MHB). All cultures were incubated
aerobically at 37 °C.
2.2. Determination of the minimal inhibitory concentration
(MIC) and minimal bactericidal concentration (MBC)
MICs and MBCs were determined in duplicate according to
the EUCAST broth microdilution protocol using flat-bottomed
96-well microtiter plates (TPP, Trasadingen, Switzerland) [12].
Temocillin (Eumedica SA, Brussels, Belgium) concentrations
tested ranged from 0.25 to 1024 μg/ml. The MIC was defined as
the lowest concentration of temocillin for which no significant
difference in optical density (λ=590 nm) was observed
between the inoculated and blank wells after 24 h incubation.MIC
(μg/ml)
MBC
(μg/ml)
MBIC
(μg/ml)
8 64 16
32 N128 32
32 N128 16
32 N128 N1024
64 N128 4
UK 32 N128 N1024
UK 256 N1024 128
Canada 16 N128 16
US 4 N 128 4
Australia 16 N128 32
8 N128 N1024
16 N128 16
tnam 8 N128 8
16 N128 64
8 N128 8
32 N128 32
8 N128 2
4 8 4
16 128 32
4 N128 128
4 16 4
2 N128 2
and 8 N128 4
Thailand 16 N 128 16
8 32 8
8 N128 4
8 N128 32
2 N128 2
4 32 2
32 N128 32
Thailand 8 N128 4
16 N128 N1024
8 N128 16
ago 4 16 32
16 512 1024
16 N1024 8
8 N128 4
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95%-confidence interval (calculated using Microsoft Excel) did
not contain zero. All MIC-determinations were performed in
duplicate and replicates never differed by more than two fold.
When a two fold difference was observed, the lowest
concentration was recorded as the MIC. A 100 μl aliquot
from the inoculated wells for which no significant difference in
optical density was observed with the blank wells, was used to
determine the number of surviving cells by conventional plate
counting. Two aliquots of 100 μl from two independent
experiments (n=4) were plated. The MBC was defined as the
lowest concentration for which no colony forming units were
recovered for all 4 replicates after 48 h incubation.2.3. Assessing the activity of antimicrobial combinations
with temocillin
To determine the activity of antimicrobial combinations a
checkerboard approach in 96-well microtiter plateswas used [12].
We tested 3 antimicrobial combinations (temocillin+ceftazidime,
temocillin+meropenem and temocillin+ tobramycin) against 4
strains (B. cenocepacia LMG 16656 and LMG 18829, B.
multivorans LMG 18822 and LMG 13010). For each antibiotic
the concentrations tested ranged from 0.25×MIC to 2×MIC in
Mueller-Hinton broth (using twofold dilutions). We also included
a well for each drug alone. Synergism was defined as a Fractional
Inhibitory Index (FIC) of 0.5 or less, a FIC of N0.5 to ≤4 was
considered nonsynergistic [12].2.4. Determination of the minimal biofilm inhibitory
concentration (MBIC)
To determine theMBIC a resazurin-based viability stainingwas
used [13]. An inoculum suspension containing ±5×107 CFU/ml
was added to the wells of a round-bottomed 96-well microtiter
plate (TPP). Following 4 h of adhesion, the supernatant was
removed and the plates were rinsed with physiological saline.
Subsequently, 200 μl of antibiotic-containing MHB (using
antibiotic concentrations identical to those in the MIC experi-
ments) or 200 μl physiological saline (=4 h control) was added
and the plates were further incubated at 37 °C. After 24 h of
treatment, the wells were again rinsed and finally 120 μl of a
commercially available resazurin solution (CellTiter-Blue, Pro-
mega, Madison, WI, USA) was added to all wells. Fluorescence
(λex 560 nm, λem 590 nm) was measured after 2 h of incubation.
The lowest concentration for which there was no significant
further growth after 4 h of adhesion was recorded as the MBIC.
Further growth was considered significant when the 95%-
confidence interval around the difference between fluorescence
obtained after 4 h of adhesion and fluorescence obtained after 4 h
of adhesion and 24 h of temocillin treatment did not contain zero.
All MBIC-determinations were performed in duplicate and
replicates never differed by more than two fold. When a two
fold difference was observed, the lowest concentration was
recorded as the MBIC.2.5. Evaluation of the bactericidal effect on mature biofilms
To evaluate the bactericidal effect of temocillin on mature
biofilms, 24 h old biofilms were exposed to a concentration of
10×MIC for 24 h. Biofilms were grown on medical-grade
silicone discs (Q7-4735, Dow Corning, Midland, MI, USA)
placed in the wells of a 24-well microtiter plate (TPP), as
described previously [13]. Three discs per strain were treated
and three untreated discs served as controls. 95%-confidence
intervals were calculated to determine whether differences in
the number of colony forming units were statistically significant
between the conditions.
3. Results and discussion
Treatment of pulmonary exacerbations in Bcc infected CF
patients is often complicated by the resistance of Bcc isolates
against many antibiotics. In the present study we investigated
the bacteriostatic and bactericidal effects of temocillin on 37
Bcc strains grown both planktonically and in a biofilm.
3.1. Determination of the MIC and MBC
The distribution of the MICs for temocillin against 37 Bcc
strains is shown in Fig. 1. Since there is no EUCAST breakpoint
available, the clinical breakpoint for resistance (MICsN16 μg/ml)
proposed by Fuchs et al. was used [14]. Although theMICs varied
widely, based on this breakpoint 28/37 strains (75.7%) were
susceptible when grown planktonically. B. pyrrocinia LMG
21824 andB. arborisLMG24066 had the lowestMICs (Table 1),
while B. multivorans LMG 18822 and B. cenocepacia LMG
16656 had MICs of 64 μg/ml and 256 μg/ml respectively. While
the majority of the strains tested were susceptible when grown
planktonically, only two of the four tested B. cenocepacia strains
and none of the four B. multivorans strains was susceptible.
Peeters et al. [13] tested six different antibiotics against the same
strain panel. Meropenem and ceftazidime, two other β-lactams,
were among the most active antibiotics as for both antibiotics
60.5% of the strains showed growth inhibition at breakpoint
antibiotic concentrations. Five strains (B. cepacia LMG 1222,
B. cenocepacia LMG 18828, B. pyrrocinia LMG 14191 and
B. metallica LMG 24068 and R-2712) were susceptible to
temocillin but not to meropenem and ceftazidime.
3.2. Assessing the activity of antimicrobial combinations
with temocillin
CF patients often have mixed infections with Bcc and
P. aeruginosa [15]. Since temocillin has no activity against
P. aeruginosa [16] we examined the effect of a combination of
temocillin with another β-lactam (ceftazidime and meropenem)
and with tobramycin, a frequently used anti-Pseudomonas
antibiotic known to be synergistic with β-lactam antibiotics
[17]. For the strains tested we could not detect synergy for
temocillin and ceftazidime (B. cenocepacia LMG 16656 and
LMG 18829: FIC=1, B. multivorans LMG 13010: FIC=0.75,
and B. multivorans LMG 18822: FIC=0.625) or meropenem
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Fig. 1. The distribution of the MICs for temocillin against 37 Bcc strains. The vertical line corresponds to the breakpoint of 16 μg/ml [14].
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18829: FIC=1, andB.multivoransLMG13010 and LMG18822:
FIC=0.75). For two strains (B. multivorans LMG 13010 and
LMG 18822) minor synergistic effects were observed for
temocillin and tobramycin (FIC=0.5 for both strains).
β-lactams exhibit time-dependent antimicrobial activity and
depending on the concentration they can act as bacteriostatic or
bactericidal antibiotics [6,18]. For temocillin, MBC values
(Table 1) obtained in the present study were high (up to more
than 64 times higher than the MICs). Only six strains had MBCs
lower than 128 μg/ml, which falls within the range of
achievable peak total concentrations (150–200 μg/ml), al-
though not in that of the minimal total plasma concentration
(28 μg/ml) [6,19]. Furthermore the concentration of available
temocillin is only 15–30% of the total values [6].5
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Fig. 2. Average number of cells present in untreated biofilms (grey bars) and in bi
significant reductions were obtained. Error bars represent standard deviations (n=3)3.3. Determination of the MBIC and the bactericidal effect
on biofilms
While biofilms are typically considered more resistant than
planktonic cells, our results confirm data obtained in a previous
study in which no remarkable difference in the resistance was
observed when exponentially growing planktonic cells and
young biofilms were compared [13] (Table 1).
Five strains (B. multivorans LMG 18825 and LMG 17588,
B. stabilis LMG 14086, B. metallica LMG 24068 and B. lata R-
9940) had MBICs above 1024 μg/ml, although the MICs were
32 μg/ml or less. However for many strains biofilm growth was
already considerably inhibited by concentrations lower than the
MBIC. Surprisingly, for B. multivorans LMG 18822 the MIC
was 16 times higher than the MBIC. A similar observationofilms treated with temocillin (white bars) for 19 strains for which statistically
.
454 H. Van Acker et al. / Journal of Cystic Fibrosis 9 (2010) 450–454was made when this strain was treated with ceftazidime, another
β-lactam [13].
After 24 h treatment with a concentration of 10×MIC,
reductions varied between 0% and 90.2%. For 19/37 strains the
reductions were statistically significant (Fig. 2). The highest
reduction (90.2%) was observed for B. contaminans LMG
16227. Similar reductions were previously observed for
ceftazidime and meropenem [13].
In conclusion temocillin has a good bacteriostatic in vitro
activity against Bcc planktonic and 4 h old biofilms, but seems
of limited use to eradicate biofilms.Acknowledgments
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